期刊文献+

增殖型和膜型狼疮性肾炎患者缓解及复发的相关因素四年随访研究 被引量:4

Analysis of associated factors for remission and relapse in proliferative and membranous lupus nephritis patients: a 4.year follow-up study
原文传递
导出
摘要 目的探讨影响狼疮性肾炎患者疗效及复发的相关因素。方法对2003年1月至2010年12月上海交通大学医学院附属仁济医院肾脏科诊断为增殖型及膜型狼疮性肾炎患者进行回顾性分析,统计患者临床病史、生化检查、免疫学指标及病理分型。根据患者是否缓解分为完全缓解(CR)组、部分缓解(PR)组和治疗无效(NR)组;根据复发情况分为复发组和未复发组,并对以上数据进行分析。结果(1)共入选105例患者,其中男6例,女99例,平均随访(51±30)个月,86例于治疗6个月后得到缓解。(2)CR组(36例)、PR组(50例)、NR组(19例)患者起病时24h尿蛋白[1.7(1.4~3.8)、4.7(3.1~7.6)、3.0(2.3~5.9)g,P〈0.01]、血肌酐[58.1(53.0—70.9)、67.5(53.5~129.1)、128.9(69.9~184.3)μmol/L,P〈0.01]、血清白蛋白f30.6(27.8~34.6)、22.4(19.3~29.4)、23.1(18.9~28.6)g/L,P〈0.01)、估算肾小球滤过率(eGFR)[128.4(107.5—156.5)、110.3(51.9—145.7)、62.4(34.8~120.3)ml·min-1·(1.73m2)-1,P〈0.01]、活动性指数评分(AI)和慢性化指数评分(CI)差异有统计学意义。(3)86例缓解患者中,随访(40.5±22.5)个月,20例(23.3%)出现复发,平均复发时间为(30.6±18.6)个月,复发组患者维持期单用激素率明显高于未复发组(15.0%比1.5%,P〈0.05)、依从性也较差(40.0%比9.1%,P〈0.01);多元回归分析表明,维持期单用激素治疗是复发的独立危险因素。结论影响患者缓解的因素有起病时尿蛋白量、血肌酐、血白蛋白、eGFR和AI评分。维持期单用激素治疗是狼疮性肾炎患者复发的独立危险因素,患者治疗依从性差可能是复发的主要影响因素之一,提高患者治疗依从性及在维持期使用激素联合免疫抑制剂治疗可有效维持疾病长期缓解,减少复发。 Objective To explore the related factors of remission and relapse in lupus nephritis (LN) patients. Methods A retrospective study was conducted for proliferation and membrane LN patients diagnosed from 2003 to 2010. Their clinical, laboratory and pathological parameters were collected. According to the response to treatment, they were divided into 3 groups of complete remission (CR), partial remission (PR) and no response (NR). Those in remission were divided into 2 groups of relapsing and non- relapsing during maintenance period. Associated factors for remission and relapse were analyzed. Results ( 1 ) Among a total of 105 patients, there were 99 females and 6 males with an average follow-up period of (51 -+ 30) months. Eighty-six patients achieved remission after 6-month treatment. (2) The outcomes were CR (n =36), PR (n =50) and NR (n = 19). Proteinuria in PR group was higher than that in CR group (4. 7 (3.1 - 7.6) vs 1.7 ( 1.4 - 3.8), P 〈 0. 01 ) while proteinuria of CR group was lower than that of NR group (1.7 (1.4 -3.8) vs 3.0 (2.3 -5.9), P 〈0.01). Serum albumin level of CR group was significantly higher than those of PR ( 30. 6 ( 27.8 - 34. 6 ) vs 22. 4 ( 19.3 - 29.4 ), P 〈 0. 01 ) and NR groups (30. 6 (27.8 - 34. 6) vs 23.1 ( 18.9 - 28.6), P 〈 0. 01 ). Serum creatinine was significantly higher in NR group than those of CR (128.9 (69. 9 - 184. 3) vs 58. 1 (53.0 -70. 9) , P 〈 0. 01 ) and PR group ( 128.9 (69.9 - 184. 3 ) vs 67. 5 (53.5 - 129.1 ), P 〈 0. 05 ). Acute index (AI) and chronic index (CI) were lower in CR group than those of PR and NR groups. (3) A total of 86 cases achieved remission (CR/PR) while 20 cases (23.3%) had relapse. During the maintenance period, the relapse rate was higher in the group on prednisone alone than those on combined therapy of prednisone plus immunosuppressant (P 〈0. 05). Sixty patients (90. 9% ) in non-relapse group and 12 cases (60. 0% ) in recurrence group had good compliance. Conclusions Initial proteinuria, serum creatinine, serum albumin, estimated glomerular filtration rate and AI were related with remission of induction period. Prednisone-alone therapy is an independent risk factor for relapse during maintenance period. Poor compliance of patients may be one of the risk factors for relapse during maintenance period. It may be useful to maintain sustained remission and reduce relapse in LN patients by improving their compliance and using steroids plus immunosuppressant during maintenance period.
出处 《中华医学杂志》 CAS CSCD 北大核心 2013年第48期3826-3830,共5页 National Medical Journal of China
基金 国家重点基础研究发展计划(2012CB517602) “十二五”国家科技支撑计划(2011BA110804、2011BA110808)
关键词 狼疮肾炎 复发 疾病缓解 危险因素 Lupus nephritis Relapse Remission Risk factors
  • 相关文献

参考文献17

  • 1Faurschou M,Dreyer L,Kamper AL. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis[J].Arthritis Care Res (Hoboken),2010.873-880.
  • 2Croca SC,Rodrigues T,Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period[J].{H}Rheumatology(Oxford),2011.1424-1430.
  • 3Mok CC,Wong RW,Lau CS. Lupus nephritis in Southern Chinese patients:clinicopathologic findings and long-term outcome[J].{H}American Journal of Kidney Disease,1999.315-323.
  • 4Houssiau FA,Vasconcelos C,D'Cruz D. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis:lessons from long-term followup of patients in the EuroLupus Nephritis Trial[J].{H}ARTHRITIS AND RHEUMATISM,2004.3934-3940.
  • 5Hui M,Garner R,Rees F. Lupus nephritis:a 15-year multi-centre experience in the UK[J].{H}LUPUS,2013.328-332.
  • 6Korbet SM,Lewis E J,Schwartz MM. Factors predictive of outcome in severe lupus nephritis.Lupus Nephritis Collaborative Study Group[J].{H}American Journal of Kidney Disease,2000.904-914.
  • 7Mok CC,Ho CT,Chan KW. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine[J].{H}ARTHRITIS AND RHEUMATISM,2002.1003-1013.
  • 8Mok CC,Ying KY,Ng WL. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide[J].{H}American Journal of Medicine,2006.325-355.
  • 9Ginzler EM,Wofsy D,Isenberg D. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis:findings in a multicenter,prospective,randomized,open-label,parallel-group clinical trial[J].{H}ARTHRITIS AND RHEUMATISM,2010.211-221.
  • 10崔太根,侯凡凡,倪兆慧,陈香美,张凤山,朱彤莹,赵学智,鲍春德,赵明辉,王国保,钱家麒,蔡广研,李英楠,陆福明,梅长林,邹万忠,王海燕.来氟米特联合糖皮质激素治疗增殖型狼疮性肾炎的多中心对照临床试验研究[J].中华内科杂志,2005,44(9):672-676. 被引量:103

二级参考文献15

  • 1刘春蓓,胡伟新,谢红浪,章海涛,陈惠萍,曾彩虹,刘志红,黎磊石.霉酚酸酯与环磷酰胺治疗Ⅳ型伴Ⅴ型狼疮性肾炎的疗效比较[J].肾脏病与透析肾移植杂志,2006,15(1):1-6. 被引量:34
  • 2钟旭辉,黄建萍,陈彦,刘景城,杨霁云.儿童狼疮性肾炎91例临床和病理分析[J].实用儿科临床杂志,2006,21(9):527-529. 被引量:9
  • 3章海涛,胡伟新,谢红浪,曾彩虹,陈惠萍,刘志红,黎磊石.前瞻性比较普乐可复与环磷酰胺诱导治疗Ⅴ型伴Ⅳ型狼疮性肾炎的疗效[J].肾脏病与透析肾移植杂志,2006,15(6):508-514. 被引量:20
  • 4Flanc RS, Roberts MA, Strippoli GF, et al.Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials.Am J Kidney Dis,2004,43:197-208.
  • 5Breedveld FC, Dayer JM.Leflunomide: mode of action in the treatment of rheumatoid arthritis.Ann Rheum Dis, 2000,59:841-849.
  • 6Li EK, Tam LS, Tomlinson B.Leflunomide in the treatment of rheumatoid arthritis.Clin Ther,2004,26: 447-459.
  • 7Remer CF, Weisman MH, Wallace DJ.Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study.Lupus,2001,10:480-483.
  • 8Tam LS, Li EK, Wong CK, et al.Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus.Lupus,2004,13:601-604.
  • 9Levey AS, Lan SP, Corwin HL, et al.Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide.Ann Intern Med,1992,116:114-123.
  • 10Smolen JS, Kalden JR, Scott DL, et al.Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.Lancet,1999,353:259-266.

共引文献108

同被引文献55

引证文献4

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部